Tests NGM120 in people with colorectal cancer and cancer cachexia
Tests NGM120 against placebo in adults with colorectal cancer and cancer cachexia.
Plain-language title generated from the registry record
Registry title: An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.
Key facts
- Where
- Budapest, Budapest VIII, and Budapest XII, HungarySee the 3 sites
- Phase
- Phase 2
Where in Hungary
- Semmelweis UniversityBudapest, HungaryTaking people
- Semmelweis UniversityBudapest VIII, HungaryTaking people
- Orszagos Onkologiai IntezetBudapest XII, HungaryTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- NGM Biopharmaceuticals, Inc
- Trial code
- NCT07033026EU 2025-521730-28-00
- Record updated
- 1 April 2026
- Original description
A multi-center evaluation of NGM120 in a randomized, double-blind, placebo-controlled study in participants with colorectal cancer who have cancer cachexia.Read full original descriptionShow less
A Phase 2, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of NGM120 in Participants With Colorectal Cancer Who Have Cancer Cachexia
A multi-center evaluation of NGM120 in a randomized, double-blind, placebo-controlled study in participants with colorectal cancer who have cancer cachexia.
Inclusion: Documented active diagnosis of colorectal cancer; Cachexia defined by Fearon criteria of weight loss; Signed informed consent.
Exclusion: Receiving tube feedings or parenteral nutrition at the time of Screening or Randomization; Current active reversible causes of decreased food intake; Have cachexia caused by other reasons.